Erasca, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Erasca, Inc. | ERAS - NASDAQ |
$14.00-$16.00 |
$16.00 |
$15.90 | 18.75 million | 7/16/2021 |
J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities
|
Co-Manager(s): |
Health Care |
Filing(s): Filed 2021-06-25 Terms Added 2021-07-12
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Erasca, Inc., and our comprehensive analysis, click "Buy Market Research".
Erasca, Inc. Quote & Chart - Click for current quote -
ERAS
About Erasca, Inc. (adapted from Erasca, Inc. prospectus):
They are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ERAS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved